117, Avenue de Luminy
BP 30191
Marseille 13009
France
33 4 30 30 30 30
https://www.innate-pharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 179
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Herve Brailly Ph.D. | Co-Founder, Interim CEO & Chairman of Executive Board | N/A | N/A | 1961 |
Mr. Yannis Morel Ph.D. | Executive VP, COO & Member of Executive Board | 387.52k | N/A | 1973 |
Dr. François Romagné Ph.D. | Founder | N/A | N/A | 1964 |
Mr. Eric Vivier D.V.M., M.B.A., Ph.D. | Founder, Senior VP & Chief Scientific Officer | N/A | N/A | 1964 |
Dr. Marc Bonneville Ph.D. | Founder | N/A | N/A | 1960 |
Mr. Jean Jacques Fournié Ph.D. | Founder | N/A | N/A | N/A |
Mr. Alessandro Moretta M.D., Ph.D. | Founder | N/A | N/A | N/A |
Mr. Frederic Lombard M.B.A. | Senior VP & CFO | N/A | N/A | 1975 |
Dr. Sonia Quaratino M.D., Ph.D. | Executive VP, Chief Medical Officer & Member of Executive Board | N/A | N/A | 1967 |
Mr. Arvind Sood | Executive VP, President of US Operations & Member of Executive Board | N/A | N/A | N/A |
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.
Innate Pharma S.A.’s ISS Governance QualityScore as of May 1, 2024 is 9. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 4; Compensation: 10.